ArticleBMJ open gastroenterology2026
Evaluating the predictive value of multiple rounds of faecal haemoglobin measurement for the prediction of advanced neoplasia and colorectal cancer: an analysis of data from the Dutch national colorectal cancer screening programme.
Article in BMJ open gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFaecal haemoglobin (f-Hb) concentrations from two screening rounds improve colorectal cancer (CRC) risk prediction, but the value of longer longitudinal data remains uncertain. This study aimed to assess whether incorporating f-Hb data from three prior screening rounds improves risk stratification for CRC and advanced neoplasia (AN).
methodsUsing data from four rounds of the Dutch national CRC screening programme (1 January 2014 and 31 December 2022), prognostic models combining age, sex, and f-Hb concentrations were developed to predict CRC and AN. Multiple representations of longitudinal f-Hb were evaluated. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), calibration, and information criteria. Risk reclassification was quantified using net reclassification improvement (NRI) and integrated discrimination improvement (IDI). The policy impact of risk-based referral, expressed as additional colonoscopies, was examined. External validation used data from a Dutch faecal immunochemical test pilot study.
resultsAmong 1 171 070 participants included, 2357 (0.2%) had CRC and 14 543 (1.2%) had AN. Models incorporating categorised f-Hb values from three prior rounds, age, and sex achieved the highest discrimination (AUC: AN 0.76 (0.75-0.77); CRC 0.73 (0.72-0.74)) and significantly improved reclassification (NRI and IDI, p<0.001). Participants in the highest 15% predicted risk had a 6.8-fold (95% CI 6.4 to 6.9) increased risk of AN and a 5.9-fold (95% CI 5.4 to 6.6) increased risk of CRC. Risk-based referral enabled earlier detection with minimal additional colonoscopy for both CRC and AN.
conclusionIncluding f-Hb data from three prior screening rounds improves CRC and AN risk prediction. Targeted referral of the highest risk individuals enables earlier detection with limited impact on colonoscopy capacity, supporting personalised CRC screening strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.